Background: Cell-free DNA (cfDNA) from plasma offers easily obtainable material for KRAS mutation analysis. Novel, multiplex, and accurate diagnostic systems using small amounts of DNA are needed to further the use of plasma cfDNA testing in personalized therapy.
Introduction
Mutations in codons 12 and 13 of the KRAS gene (KRAS G12/G13 mutations) are prevalent in colorectal cancer, non-small cell lung cancer (NSCLC), and others and can be associated with less favorable prognosis or a lack of benefit from anti-epidermal growth factor receptor antibodies [1] [2] [3] [4] [5] [6] . Furthermore, preclinical and early clinical data suggest that KRAS mutations can predict the response of advanced low-grade serous ovarian cancer to combinations of PI3K and MEK inhibitors [7] . Therefore, the accurate assessment of KRAS mutation status is critical to therapeutic decisions.
Current practice prescribes KRAS mutation testing of archival formalin-fixed, paraffin-embedded (FFPE) tumor tissue and a lack of adequate samples can preclude mutation analysis in at least 10% of patients with advanced cancers [8] . Also, mutation status can change over time, and discrepancies between the genomic profiles of primary and metastatic tumors may occur [9] [10] [11] . Thus, archival FFPE tumor samples, which may be many years old, might not necessarily reflect the pertinent genotype.
Cell-free DNA (cfDNA) is secreted into the circulation by tumor cells and cells in the tumor microenvironment that are undergoing apoptosis or necrosis and can be isolated from plasma as a minimally invasive alternative for determining KRAS mutation status by polymerase chain reaction (PCR) or nextgeneration-sequencing (NGS) methods [12] . Droplet digital PCR (ddPCR) has better sensitivity than standard quantitative PCR or NGS and simpler workflow than other digital PCR such as BEAMing [12] . The purpose of the present study of patients with advanced cancer was to determine whether the detection and quantification of KRAS G12/G13 mutations in unamplified plasma cfDNA by multiplexed ddPCR has an acceptable level of sensitivity, specificity and concordance with conventional clinical testing for KRAS mutations in FFPE tumor samples performed by a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory. We also sought to determine whether the number of KRAS G12/G13 mutant alleles in the wild-type background (mutant allele frequency [MAF] or copy number) is associated with outcomes.
Methods Patients
The study enrolled patients with progressing advanced cancers and known KRAS G12/G13 mutation status from clinical testing of their FFPE specimens (supplementary Methods, available at Annals of Oncology online) who were referred to MD Anderson's Department of Investigational Cancer Therapeutics for experimental therapies from October 2010 to June 2015. Patients had the option of providing longitudinally collected plasma samples during the course of their therapy (at baseline, then every 3-4 weeks if feasible). This retrospective study was conducted in accordance with MD Anderson's Institutional Review Board guidelines.
Plasma collection and cfDNA KRAS
G12/G13 mutation testing Whole blood was collected in EDTA-containing tubes and centrifuged and spun twice within 2 h to yield plasma. The QIAamp Circulating Nucleic Acid kit (Qiagen, Valencia, CA) was used to isolate cfDNA according to the manufacturer's instructions, and 16 ng of unamplified cfDNA was tested with a multiplex ddPCR KRAS G12/G13 Screening Kit (Bio-Rad, Pleasanton, CA) to distinguish the wild-type allele from the seven most common mutations in the exon 2 (G12A, G12C, G12D, G12R, G12S, G12V, and G13D) using the QX200 Droplet Digital PCR platform (Bio-Rad) according to the manufacturer's standard protocol (supplementary Table S1 , available at Annals of Oncology online). Mutation-specific assays (e.g. G12V, G12D) or more cfDNA (24-100 ng) were used for re-testing for patients whose FFPE specimens but not plasma cfDNA showed a KRAS G12/G13 mutation. The investigators performing the mutation analysis of the cfDNA samples were blinded to the results of the FFPE specimens and used appropriate positive and negative controls. The lower limit of detection is approximately 0.2% MAF for the multiplexed screening assay and <0.1% MAF per single well for the mutation-specific assays.
Statistical analysis
Concordance between the mutation analyses of FFPE specimens and plasma cfDNA was calculated using a kappa coefficient. Overall survival (OS) was defined as the time from the date of study entry to the date of death or last follow-up. Time to treatment failure (TTF) was defined as the time from the date of systemic therapy initiation to the date of removal from the treatment. The Kaplan-Meier method was used to estimate OS and TTF, and a log-rank test was used to compare OS and TTF among patient subgroups. Cox proportional hazards regression models were fit to assess the association between patient characteristics and OS or TTF. The Spearman rank coefficient was used to assess correlations. All tests were two-sided, and P values <0.05 were considered statistically significant. All statistical analyses were performed with the GraphPad (GraphPad Software, Inc., La Jolla, CA) or SPSS 23 (SPSS, Chicago, IL) software programs.
Results

Patients
The study enrolled 121 patients with diverse advanced cancers and known KRAS G12/G13 mutation statuses of archival FFPE specimens ( Table S2 and File S1, available at Annals of Oncology online).
Sixteen nanograms of cfDNA contain only about 5000 genomic equivalents, which enabled us to reliably detect KRAS G12/G13 mutations in samples with a MAF of 0.2%. In the 14 cases with known KRAS G12/G13 mutations in FFPE specimens but wild-type KRAS in cfDNA, we were able to detect KRAS G12/G13 mutations in the cfDNA in seven cases by increasing the amount of cfDNA (median, 74 ng; range, 24-100 ng) and in an additional three cases using mutation-specific probes (G12V, G12D) and 49-100 ng of cfDNA. This yielded overall agreement between cfDNA and FFPE specimens in 113 cases (93%; kappa, 0.83; SE, 0.06; 95% CI, 0.72-0.95), and the cfDNA test had a sensitivity of 95% (95% CI, 0.89-0.99), specificity of 88% (95% CI, 0.72-0.97), PPV of 95% (95% CI, 0.89-0.99), and NPV of 88% (95% CI, 0.72-0.97; Table 2 ).
Furthermore, we were able to retrieve archival FFPE specimens for 2 of 4 cases with KRAS G12/G13 mutations in cfDNA but wild-type KRAS in FFPE specimens and using ddPCR identified lowfrequency KRAS G12/G13 mutations in both of them (0.08% and 0.14%, respectively). This yielded overall agreement between cfDNA and FFPE specimens in 115 cases (95%; kappa, 0.87; SE, 0.05; 95% CI, 0.77-0.97), and the cfDNA test had a sensitivity of 96% (95% CI, 0.89-0.99), specificity of 94% (95% CI, 0.79-0.99), PPV of 98% (95% CI, 0.92-1.00), and NPV of 88% (95% CI, 0.72-0.97; Table 2 ). Of interest, 1 of 4 patients who had KRAS G12/G13 mutations in cfDNA but wild-type KRAS in FFPE specimens had advanced colorectal cancer and received chemotherapy with cetuximab, which resulted in accelerated disease progression (supple mentary Figure S1 , available at Annals of Oncology online).
KRAS
G12/G10 mutations in cfDNA and survival
To determine whether the baseline MAF of KRAS G12/G13 -mutated cfDNA was associated with OS, we divided the 121 patients into two groups according to the percentage of KRAS G12/G13 -mutated cfDNA (MAF <6.2% versus MAF 6.2%). These thresholds were selected based on a 5% trimmed mean value of KRAS G12/G13 -mutated cfDNA. This was deemed to be representative, as the median percentage of KRAS G12/G13 -mutant cfDNA was only 0.5% because 33 of 121 patients had no KRAS G12/G13 mutations in cfDNA. The median OS of the 82 patients with a KRAS G12/G13 -mutant cfDNA MAF <6.2% (7.5 months; 95% CI, 5.6-9.4 months) was significantly longer than that of the 39 patients with a KRAS G12/G13 -mutant cfDNA MAF 6.2% (5.4 months; 95% CI, 3.7-7.1 months; P ¼ 0.001; Figure 1A ). Similarly, when we used a median percentage of KRAS G12/G13 -mutant cfDNA (<0.5% versus 0.5%) as the cut-off value, the median OS of the 60 patients with a KRAS G12/G13 -mutant cfDNA MAF <0.5% (8.4 months; 95% CI, 5.5-11.3 months) was significantly longer than that of the 61 patients with a KRAS G12/G13 -mutant cfDNA MAF 0.5% (5.5 months; 95% CI, 4.7-6.3 months; P ¼ 0.004; supplementary Figure S2A , available at Annals of Oncology online). We also performed a separate analysis for patients with colorectal cancer (N ¼ 71, the most frequent cancer type) and found that the median OS of the 41 patients with a KRAS G12/G13 -mutant cfDNA MAF <6.2% (8.4 months; 95% CI, 5.1-11.7 months) was significantly longer than that of the 30 patients with a KRAS G12/G13 -mutant cfDNA MAF 6.2% (5.7 months; 95% CI, 3.8-7.6 months; P ¼ 0.007; supplementary Figure S2B , available at Annals of Oncology online). In contrast, neither the amount of total cfDNA in plasma (ng/ml) nor the cfDNA concentration (ng/ml) was associated with OS (supplementary Figure  S2C and D, available at Annals of Oncology online). Finally, in a -mutant cfDNA percentage of <4.0% (7.3 months; 95% CI, 3.6-11.0; blue) was significantly longer than that of the 44 patients with a KRAS G12/G13 -mutant cfDNA percentage of 4.0% (5.5 months; 95% CI, 4.3-6.7; red; P ¼ 0.017).
separate analysis of patients with KRAS G12/G13 mutations in FFPE specimens, the median OS of the 44 patients with a MAF <4% (7.3 months; 95% CI, 3.6-11.0 months) was significantly longer than that of the 44 patients with a MAF 4% (5.5 months; 95% CI, 4.3-6.7 months; P ¼ 0.017; Figure 1B) .
Next, we analyzed the prognostic impact of the MAF of KRAS G12/G13 -mutant cfDNA on OS using a multi-variable analysis, which included the Royal Marsden Hospital (RMH) prognostic score [13] . The RMH score, a prospectively validated tool used to predict OS in patients with advanced cancers who are referred for early phase clinical trials, is calculated on the basis of lactate dehydrogenase levels (greater than the upper limit of normal versus normal), albumin levels (<3.5 g/ml versus 3.5 g/ml), and the number of metastatic sites (>2 sites versus 2 sites). Scores of 0 or 1 are associated with longer OS than are scores of 2 or 3. The median OS duration of the 70 patients with an RMH score of 0 or 1 (8.4 months; 95% CI, 5.7-11.1 months) was significantly longer than that of the 51 patients with an RMH score of 2 or 3 (4.4 months; 95% CI, 2.4-6.4 months; P < 0.001). A multi-variable analysis including all 121 patients revealed that, compared to an RMH score of 2 or 3, an RMH score of 0 or 1 was associated with longer OS (hazard ratio [HR], 0.57; 95% CI, 0.36-0.90; P ¼ 0.015 ; Table 3 ) and that, compared to a KRASmutant cfDNA MAF 6.2%, a KRAS G12/G13 -mutant cfDNA MAF <6.2% demonstrated a trend towards longer OS (HR, 0.63; 95% CI, 0.39-1.02; P ¼ 0.06; Table 3 ). An additional multivariable analysis including 88 patients with KRAS G12/G13 mutations in FFPE (patients with wild-type KRAS in cfDNA were excluded), which included RMH score (0 or 1 versus 2 or 3) and KRAS G12/G13 -mutant percentage of cfDNA (4.0% versus <4.0%), demonstrated that a KRAS G12/G13 -mutant cfDNA percentage <4.0% (HR, 0.64; 95% CI, 0.39-1.06; P ¼ 0.08) but not RMH score was associated with a trend towards longer OS (HR, 0.68; 95% CI, 0.42-1.13; P ¼ 0.14; Table 3 ).
Longitudinal testing for KRAS G12/G13 mutations in plasma cfDNA
At least two (median, 4; range, 2-12) longitudinal serial plasma collections were obtained before and during systemic therapy from 23 patients with KRAS G12/G13 mutations in FFPE specimens who underwent 26 diverse experimental systemic therapies (Figure 2 and supplementary Figure S3 , available at Annals of Oncology online). In all 23 patients, KRAS G12/G13 mutations were detected in plasma cfDNA at 1 time points. Because MAF might be influenced by the number of wild-type copies, which can vary for reasons other than cancer, we also analyzed changes in the number of KRAS G12/G13 copies per 1 ml of plasma, which did not take into account wild-type copies [12] . The median KRAS G12/G13 MAFs at baseline (0.50%), during therapy (0.22%), and at disease progression (1.13%) differed significantly (P ¼ 0.04), as did the median numbers of KRAS G12/G13 copies at baseline (14) , during therapy (17) and at disease progression (273; P ¼ 0.03; Figure 3) . The best response to therapy on imaging per Response Evaluation Criteria in Solid Tumors (RECIST) was not correlated with the best change in MAF (r ¼ 0.26; P ¼ 0.21) but was correlated with the best change in the number of KRAS G12/G13 copies (r ¼ 0.42; P ¼ 0.04) [14, 15] . Of the 26 diverse systemic cancer therapies, 12 decreased the KRAS G12/G13 MAF, 14 caused no change or increased the KRAS G12/G13 MAF, 11 decreased the number of KRAS G12/G13 copies, and 15 caused no change or increased the number of KRAS G12/G13 copies. The median TTFs of patients with a decrease in KRAS G12/G13 MAF (2.5 months) and those with no change or an increase in KRAS G12/G13 MAF (2.8 months) did not differ significantly (P ¼ 0.72); however, there was a trend towards longer TTF for decrease in number of KRAS G12/G13 copies compared to no change or increase (3.4 months versus 2.7 months; P ¼ 0.11; supple mentary Figure S4 , available at Annals of Oncology online). Nevertheless, decrease in size of target tumor lesions on imaging per RECIST vs. no change or increase was the only variable significantly associated with prolonged median TTF (8.2 months versus 2.5 months; P ¼ 0.001; supplementary Figure S4 , available at Annals of Oncology online).
Discussion
Our findings demonstrate that the ddPCR KRAS multiplex assay of a small amount of unamplified, plasma cfDNA from patients with advanced cancers can detect KRAS G12/G13 mutations and has acceptable concordance (85%), sensitivity (84%), and specificity (88%) compared with the CLIA-certified laboratory-based testing of FFPE tumor tissue obtained at different times during routine care. The addition of more cfDNA with or without the use of mutation-specific probes, as well as retesting discrepant FFPE specimens with ddPCR, resolved the majority of discrepancies between cfDNA and tumor tissue and increased concordance, sensitivity, and specificity to 95%, 96%, and 94%, respectively. We recently demonstrated in a similar patient population that the testing of plasma cfDNA for KRAS G12/G13 mutations with BEAMing PCR is concordant with the standard-of-care mutation analysis of FFPE primary or metastatic tumor in 83% of cases, which is similar to the results obtained with the ddPCR KRAS multiplex assay in the present study [16] . A certain level of discordance can be anticipated if the tumor tissue and plasma are not obtained at the same time. Higgins et al. [17] found 100% agreement between PIK3CA mutation testing of plasma cfDNA with BEAMing PCR and tumor tissue collected in a cohort of patients with advanced breast cancer and simultaneous collection. However, the concordance between the methods decreased to 79% in a cohort of patients whose tumor and plasma cfDNA samples were obtained at different times, which is consistent with Figure 2 . Dynamic changes in KRAS G12/G13 -mutated cfDNA in various patients with heavily pretreated KRAS G12/G13 -mutated advanced cancers. In each panel, the top graph depicts the KRAS G12/G13 mutation allelic frequency (MAF) in the wild-type background, and the bottom graph depicts the number of KRAS G12/G13 copies per 1 ml of plasma. Red arrows indicate the onset of progressive disease. Shown are sequential measurements of KRAS G12/G13 (blue); cancer antigen 125 (CA125) levels (panels A and C), cancer antigen 15-3 (CA15-3) levels (panel B), carcinoembryonic antigen (CEA) levels (panels D-F; orange); and the sum (cm) of target lesions on imaging (grey bars) in (A) a patient with metastatic ovarian carcinoma who received targeted therapy with an ERK inhibitor; (B) a patient with metastatic breast carcinoma who received therapy with an mTOR inhibitor, HDAC inhibitor, and anti-VEGF antibody; (C) a patient with metastatic ovarian carcinoma who received targeted therapy with PI3K and MEK inhibitors; (D) a patient with metastatic ampullary carcinoma who received targeted therapy with a MEK inhibitor.
previously published studies despite the fact that we used a very low amount of cfDNA, which in most cases was isolated from much less than 0.5 ml of plasma [17] [18] [19] [20] [21] . Collectively, there is increasing evidence that the mutation analysis results for cfDNA are highly concordant with those for archival tumor tissue for concordantly, but not discordantly, collected samples, which may be explained by tumor biology, including heterogeneity and evolution over time [10, 21] . In addition, our KRAS G12/G13 multiplex assay detects seven of the most frequent KRAS G12/G13 mutations in one reaction; in other PCR approaches, this would require seven separate tests. At the same time, the KRAS G12/G13 multiplex ddPCR assay, unlike next-generation sequencing, does not compromise on sensitivity [12] .
In the present study, we did not use pre-amplification or other methods of enrichment to detect KRAS
G12/G13
-mutant alleles, as we believe that such approaches can skew KRAS G12/G13 MAF or copy number values, which can have important prognostic significance. Indeed, we found that patients with a low KRAS G12/G13 -mutant cfDNA MAF had a significantly longer median OS duration than patients with a high KRAS G12/G13 -mutant cfDNA MAF did (7.5 months versus 5.4 months; P ¼ 0.001) and confirmed these trend in multivariable analysis, which included prospectively validated RMH score. We previously used BEAMing PCR to assess plasma cfDNA for KRAS G12/G13 mutations in patients with advanced cancers and found that a high amount of KRAS-mutant cfDNA was associated with shorter OS (4.8 months versus 7.3 months; P ¼ 0.008) [16] . In another study, using the Idylla system (Biocartis, Mechelen, Belgium) to detect BRAF V600 mutations in plasmaderived cfDNA from patients with diverse advanced cancers, we also found that a higher percentage of BRAF V600 -mutant cfDNA was associated with shorter OS (4.4 months versus 10.7 months, P ¼ 0.005) and, in patients treated with BRAF and/or MEK inhibitors, shorter TTF (3.0 versus 7.4 months, P ¼ 0.001) [22] . Similarly, high baseline levels of KRAS-mutant cfDNA were found to be Figure 2 . (E) a patient with colorectal cancer who received an intratumoral autologous dendritic cell vaccine; and (F) a patient with non-small cell lung cancer who received targeted therapy with a FGFR inhibitor. associated with shorter OS in patients with advanced colorectal cancer who were treated in a phase III randomized trial of regorafenib versus placebo [18] . Also, higher amounts of KRAS-mutant cfDNA were associated with shorter progression-free survival and OS in patients with advanced colorectal cancer treated with irinotecan and cetuximab and in patients with advanced NSCLC treated with carboplatin and vinorelbine [23, 24] . Similarly, a BRAF V600E mutation in cfDNA was associated with shorter OS in a combined analysis of clinical trials of BRAF and MEK inhibitors in patients with advanced melanomas [25] .
The detection of molecular aberrations can be used to monitor therapy response [26] [27] [28] [29] [30] [31] . In the present study, we assessed serially collected plasma cfDNA from patients treated with systemic therapies and found that the KRAS G12/G13 MAFs and copy numbers before therapy, during therapy, and at the time of disease progression differed significantly. In addition, the number of KRAS G12/G13 copies but not the KRAS G12/G13 MAF was correlated with radiographic response, perhaps because KRAS G12/G13 MAF is influenced by the amount of wild-type DNA, which can vary for reasons other than cancer (e.g. inflammation, exertion) [12] . We did not find an association between changes in KRAS G12/G13 mutations in cfDNA and TTF, which may have been due to the small number of patients in the study and the lack of an effective KRAS inhibitor in clinical testing. Although several previous studies' findings have supported the concept that changes in cfDNA can predict or at least correspond with treatment outcomes overall the evidence remains conflicting [20, 21, [29] [30] [31] [32] .
In summary, the molecular analysis of a small amount of unamplified cfDNA for KRAS G12/G13 mutations using a ddPCR multiplex assay to detect the most frequent seven hotspot mutations is feasible and has good concordance with standard mutation testing of discordantly collected FFPE tumor tissue. Our results also suggest that the number of KRAS G12/G13 -mutant alleles in cfDNA is a prognostic biomarker for OS. Our study had several potential limitations. First, we investigated only KRAS G12/G13 mutations, which are clinically relevant to only a limited number of patients with certain tumor types. Second, because the study retrospectively analyzed OS data, its findings with regard to these measures need to be validated in future prospective studies. Third, we used archival tumor tissue, which was not collected at same time as plasma samples. Fourth, more than half of the patients had colorectal cancer, which could have influenced our results. Finally, despite the clinical utility of cfDNA mutation testing is increasingly accepted additional prospective clinical trials in which therapeutic interventions are tailored on the basis of patients' respective cfDNA mutation statuses are needed.
